Dennis J. Slamon - Concepedia

Author

Dennis J. Slamon

University of California, Los Angeles ORCID

Also Known As

B. Young, D J Slamon, D SLAMON, D Slamon, D. J. Slamon, D. Slamon, D.J. Slamon, DENNIS J. SLAMON, DENNIS SLAMON, Dennis J Slamon

985

Publications

99.4K

Citations

126

H-Index

185

Concepts

All Affiliations

University of California, Los Angeles University of Southern California UCLA Jonsson Comprehensive Cancer Center Pfizer (United States)The University of Texas MD Anderson Cancer Center

About

Dennis J. Slamon is an author at University of California, Los Angeles specializing in medicine, oncology, and tumor biology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	73	162	29.5K
2	Health Sciences	18	27	4.5K
3	Natural Sciences	7	7	1.7K
4	Engineering	5	5	342
5	Allergy	1	1	73

Dennis J. Slamon

307

Publications

92.5K

Citations

117

H-Index

Page 1

	Year	Citations
Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/<i>neu</i>Oncogene Dennis J. Slamon, Gary M. Clark, Steven Wong, Science	1987	11.6K
Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2 Dennis J. Slamon, Brian Leyland‐Jones, Steven Shak, New England Journal of Medicine	2001	11.4K
Studies of the HER-2/ <i>neu</i> Proto-Oncogene in Human Breast and Ovarian Cancer Dennis J. Slamon, William Godolphin, Lovell A. Jones, Science	1989	6.8K
Palbociclib and Letrozole in Advanced Breast Cancer Richard S. Finn, Miguel Martín, Hope S. Rugo, New England Journal of Medicine	2016	2.8K
Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic Disease Melody Cobleigh, Charles L. Vogel, Debu Tripathy, Journal of Clinical Oncology	1999	2.8K
Adjuvant Trastuzumab in HER2-Positive Breast Cancer Dennis J. Slamon, W. Eiermann, Nicholas J. Robert, New England Journal of Medicine	2011	2.7K
Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses Katherine B. Chiappinelli, Pamela L. Strissel, Alexis Desrichard, Cell ChromatinEpigenetic ChangeDna MethylationImmunologyEpigenomics	2015	1.9K
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study Richard S. Finn, John Crown, István Láng, The Lancet Oncology Cyclin-dependent Kinase 4/6Breast OncologyInhibitor PalbociclibMedicinePharmacology	2014	1.9K
Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of <i>HER2</i>-Overexpressing Metastatic Breast Cancer Charles L. Vogel, Melody Cobleigh, Debu Tripathy, Journal of Clinical Oncology Breast OncologySingle AgentMedicineCancer ManagementPharmacology	2002	1.8K
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial Massimo Cristofanilli, Nicholas C. Turner, Igor Bondarenko, The Lancet Oncology Breast OncologyHealth SciencesMedicinePharmacologyClinical Trials	2016	1.8K

Page 1